Drugmaker Eli Lilly said it's seeking FDA approval of its drug Mounjaro to treat weight loss.
As more Americans turn to drugs like Ozempic and Wegovy to slim down, a new obesity medicine is showing even better results, and it could soon upend the market.
Based on the new, unprecedented results, Eli Lilly announced plans to seek fast-track approval from the U.S. Food and Drug Administration to advertise and sell the drug for weight management. It could gain authorization by the end of this year."Based on these results, Lilly plans to complete the U.S. submission for tirzepatide in adults with obesity or overweight with weight-related comorbidities in the coming weeks," the company said.
Industry experts predict that it could become one of the best-selling drugs ever, outpacing similar drugs like Ozempic and Wegovy, both of which have gained widespread popularity after gaining FDA approval to manage weight. While these new medications can have side effects, they're considered much less severe than those of obesity drugs in the past. For Mounjaro,"the most common side effects reported by patients were nausea, diarrhea and decreased appetite."
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidanceEli Lilly & Co. shares rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance....
Read more »
People with diabetes lost up to 34 pounds taking Eli Lilly drug, company saysAn Eli Lilly drug helped obese patients with Type 2 diabetes lose 15% of their body weight, or about 34 pounds, on average, in a late-stage clinical trial, the drugmaker says.
Read more »
Eli Lilly Pushes For Fast-Track Approval Of Mounjaro As Weight-Loss DrugLate-stage trials suggest Lilly’s tirzepatide, sold under Mounjaro, could be a more effective obesity drug that Ozempic or Wegovy, and the company expects a regulatory decision by the end of the year.
Read more »
Eli Lilly raises annual profit forecast on strength of diabetes drugEli Lilly and Co on Thursday raised its annual revenue and profit forecasts after topping first-quarter sales estimates on demand for its closely watched diabetes drug Mounjaro, ahead of a decision on its use as a treatment for obesity.
Read more »
Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 poundsEli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.
Read more »
Breakingviews - Eli Lilly races rising obesity expectationsThe race is on between Mounjaro’s growth and investors’ burgeoning hopes. The drug made by Eli Lilly , which was approved in May to treat diabetes, reaped an astonishing $569 million of revenue in the first quarter less than a year after it was approved for sale. The results encouraged Lilly to raise its annual profit guidance by 3.5%. Investors are counting on that growth becoming exponential.
Read more »